Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

LEO Pharma’s Eczema Drug Wins FDA Approval

LEO Pharma’s Eczema Drug Wins FDA Approval

With 2021 nearly over, LEO Pharma has scored a big victory with Adbry (tralokinumab-ldrm), earning the FDA’s blessing for treating moderate-to-severe eczema (atopic dermatitis). The approval marks the Denmark-based company’s first U.S. biologic.

The injectable monoclonal antibody is now the first and only FDA-approved biologic that specifically attaches to and acts on the IL-13 cytokine, which is known to play a big role in the signs and symptoms of the common skin condition.

The agency’s approval appears to justify LEO Pharma’s $115 million gamble five years ago to buy the exclusive global rights to AstraZeneca’s (AZ) tralokinumab in atopic dermatitis and any other future dermatology indications. At the time, AZ was still evaluating the drug as a severe asthma treatment; the last word on that was in 2017, when it failed two pivotal asthma trials.

Besides the FDA approval, tralokinumab has seen a stellar year, earning regulatory approvals in the EU, UK, Canada and the United Arab Emirates.

January 4, 2022

https://www.fdanews.com/


0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies